{"id":1274,"date":"2016-09-22T18:01:31","date_gmt":"2016-09-22T12:31:31","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1274"},"modified":"2021-07-24T12:56:32","modified_gmt":"2021-07-24T07:26:32","slug":"business-cocktail-4","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4","title":{"rendered":"Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a016138352f5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a016138352f5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\/#Collaboration_between_Sygnis_AG_and_ECACC_for_licensing_and_distribution_of_Caco-2_cell_line\" >Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\/#Partnership_between_BioNTech_and_Genentech_to_develop_individualized_mRNA_cancer_therapies\" >Partnership between BioNTech and Genentech to develop individualized mRNA cancer therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\/#Partnership_between_Zydus_Cadila_and_Takeda_to_develop_vaccine_for_Chikungunya_virus\" >Partnership between Zydus Cadila and Takeda to develop vaccine for Chikungunya virus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\/#Global_Agreement_between_Regeneron_Pharmaceuticals_Inc_and_Teva_Pharmaceutical_to_develop_Regenerons_Fasinumab\" >Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical to develop Regeneron\u2019s Fasinumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\/#Big_Pharma_companies_including_Cipla_Wockhardt_in_global_alliance_to_fight_drug_resistance\" >Big Pharma companies including Cipla &amp; Wockhardt in global alliance to fight drug resistance<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Collaboration_between_Sygnis_AG_and_ECACC_for_licensing_and_distribution_of_Caco-2_cell_line\"><\/span>Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis&#8217; Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from Sygnis in the US and afterwards will provide the Caco-2 materials directly.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Partnership_between_BioNTech_and_Genentech_to_develop_individualized_mRNA_cancer_therapies\"><\/span>Partnership between BioNTech and Genentech to develop individualized mRNA cancer therapies<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">BioNTech has agreed to collaborate with Roche\u2019s Genentech to develop and commercialize mRNA based, individualized cancer vaccines. The agreement will see the companies jointly develop individually tailored mRNA cancer vaccines applicable against a wide range of cancers, in a bid to potentially provide a new treatment paradigm for cancer patients.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Partnership_between_Zydus_Cadila_and_Takeda_to_develop_vaccine_for_Chikungunya_virus\"><\/span>Partnership between Zydus Cadila and Takeda to develop vaccine for Chikungunya virus<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Zydus Cadila and Takeda Pharmaceutical have agreed to partner to develop a vaccine for&nbsp;an emerging infectious disease known as Chikungunya. The agreement will see both parties collaborating from an early stage development of the vaccine up to its final commercialization.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Global_Agreement_between_Regeneron_Pharmaceuticals_Inc_and_Teva_Pharmaceutical_to_develop_Regenerons_Fasinumab\"><\/span>Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical to develop Regeneron\u2019s Fasinumab<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Regeneron and Teva entered a global agreement for the development and commercialization of the former\u2019s NGF antibody, fasinumab. According to the developmental deal, Regeneron will receive payment of $250 million along with development and regulatory milestone payments, plus additional payments based on net sales. Regeneron will be responsible for the global development and commercialization of fasinumab in the U.S., and Teva will be responsible for the candidate\u2019s development and commercialization outside the U.S.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Big_Pharma_companies_including_Cipla_Wockhardt_in_global_alliance_to_fight_drug_resistance\"><\/span>Big Pharma companies including Cipla &amp; Wockhardt in global alliance to fight drug resistance<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">13 global pharmaceutical companies have joined hands in laying out a roadmap to combat antimicrobial resistance (AMR) by 2020. The roadmap by these 13 drug firms follows the Industry Declaration signed in January 2016 at the World Economic Forum by more than 100 companies and trade associations, the companies said in a joint statement. The other companies in the alliance include global majors such as Johnson &amp; Johnson, Novartis, Pfizer, Sanofi and AstraZeneca.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis&#8217; Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from Sygnis in the US and afterwards [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[5423,796,96,1287,17319,17339,17336,17338,1135,423,460,1510,533,17335,554,17337,17272,17334],"industry":[17225],"therapeutic_areas":[17231,17228,17278],"class_list":["post-1274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amr","tag-antimicrobial-resistance","tag-astrazeneca","tag-biontech","tag-cipla","tag-drug-resistance","tag-ecacc","tag-fasinumab","tag-genentech","tag-novartis","tag-pfizer","tag-regeneron-pharmaceuticals","tag-sanofi","tag-sygnis-ag","tag-takeda","tag-therapies","tag-wockhardt","tag-zydus-cadila","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sygnis AG &amp; ECACC Collaboration; BioNTech &amp; Genentech collaboartion<\/title>\n<meta name=\"description\" content=\"Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis&#039; Caco-2 business. Under the collaboration, ECACC will organize...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sygnis AG &amp; ECACC Collaboration; BioNTech &amp; Genentech collaboartion\" \/>\n<meta property=\"og:description\" content=\"Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis&#039; Caco-2 business. Under the collaboration, ECACC will organize...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-22T12:31:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"602\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sygnis AG & ECACC Collaboration; BioNTech & Genentech collaboartion","description":"Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4","og_locale":"en_US","og_type":"article","og_title":"Sygnis AG & ECACC Collaboration; BioNTech & Genentech collaboartion","og_description":"Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize...","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-09-22T12:31:31+00:00","article_modified_time":"2021-07-24T07:26:32+00:00","og_image":[{"width":602,"height":339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4","name":"Sygnis AG & ECACC Collaboration; BioNTech & Genentech collaboartion","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","datePublished":"2016-09-22T12:31:31+00:00","dateModified":"2021-07-24T07:26:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-4"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-4#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","width":602,"height":339},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AMR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Antimicrobial resistance<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioNTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cipla<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Drug Resistance<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ECACC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Fasinumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sygnis AG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wockhardt<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zydus Cadila<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AMR<\/span>","<span class=\"advgb-post-tax-term\">Antimicrobial resistance<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">BioNTech<\/span>","<span class=\"advgb-post-tax-term\">Cipla<\/span>","<span class=\"advgb-post-tax-term\">Drug Resistance<\/span>","<span class=\"advgb-post-tax-term\">ECACC<\/span>","<span class=\"advgb-post-tax-term\">Fasinumab<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Regeneron Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Sygnis AG<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>","<span class=\"advgb-post-tax-term\">Therapies<\/span>","<span class=\"advgb-post-tax-term\">Wockhardt<\/span>","<span class=\"advgb-post-tax-term\">Zydus Cadila<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 22, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 22, 2016 6:01 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1274"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1040"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1274"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1274"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}